Replies to post #154630 on Biotech Values

[mcbio]

Yep agree with that. I still think it could create an interesting buying opportunity if they do get the axe and shares get crushed. I'm on the sidelines so I have no problem if that happens. But this still seems unlikely given how far along the custirsen pivotals are.

[genisi]

This makes me incrementally more nervous for OGXI, as clearly not getting the axe before the R&D day doesn't mean you are home free...

But on the relaxing side custirsen was mentioned as an expected launch so looks quite safe from the axe for now.

[DewDiligence]

This makes me incrementally more nervous for OGXI, as clearly not getting the axe before the R&D day doesn't mean you are home free...

True. The bottom line is that Teva is a very different company now than it was a few years ago. (The prospect of the end of Copaxone exclusivity in less than two years made the status quo an unappealing option.)